Every 8-K that LYRA THERAPEUTICS INC (LYRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LYRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LYRA filings page.
Lyra Therapeutics, Inc. has terminated its sublease for approximately 23,704 rentable square feet at 880 Winter Street in Waltham, Massachusetts. The sublease, originally dated December 21, 2023, terminated effective March 31, 2026, with the premises to be surrendered no later than May 31, 2026.
As part of the termination, Lyra agreed to pay a termination payment of $2,100,000.00. After Lyra completes its surrender obligations and this payment is made, RVAC Medicines (US), Inc. will release and return Lyra’s $600,501.32 letter of credit security deposit. The company’s rent obligations under the sublease ended on January 31, 2026.
Lyra Therapeutics is exiting two Massachusetts office leases earlier than planned in exchange for cash payments and forfeited deposits. The company agreed with ARE-480 Arsenal Street, LLC to end its 480 Arsenal Way lease for approximately 22,343 rentable square feet no later than May 31, 2026, instead of April 30, 2027. Lyra will forfeit a $302,514.84 letter of credit security deposit, pay a $1,000,000.00 lease modification amount, and potentially pay up to $1,500,000.00 more if a defined sale transaction closes. Rent obligations for this site ended as of January 31, 2026.
For its 880 Winter Street, Waltham lease covering approximately 28,858 rentable square feet, Lyra entered a termination agreement with BXP Waltham Woods LLC to end the lease on May 31, 2026 instead of June 30, 2033. The company will forfeit a $1,089,389.00 letter of credit security deposit and pay a $1,500,000.00 termination fee as liquidated damages, with rent obligations ending March 31, 2026. The agreement includes mutual releases effective at termination.
Lyra Therapeutics, Inc. reported that it has withdrawn its appeal of Nasdaq’s February 2, 2026 delisting determination. As a result, Nasdaq has confirmed that trading in the company’s common stock will be suspended at the open of trading on Tuesday, March 17, 2026.
Nasdaq has also indicated it will file a Form 25 Notification of Delisting with the SEC after its internal procedural periods are completed. The company’s shares are currently listed on The Nasdaq Capital Market under the symbol LYRA.
Lyra Therapeutics, Inc. reported that on February 23, 2026 it received a notice of default from RVAC Medicines (US), Inc. under its sublease for office space in Waltham, Massachusetts. The default stems from unpaid rent invoices from the master landlord totaling $484,431.92 as of the notice date.
The company previously disclosed that it is ceasing operations and preparing for a wind-down while pursuing strategic options, and has been trying to settle obligations, including lease liabilities, outside a bankruptcy process. Lyra had proposed terminating the sublease with a premises surrender date of January 31, 2026, but no agreement was reached before rent payments stopped.
Lyra states it is continuing to evaluate options regarding the sublease and other outstanding obligations as part of its wind-down. It cautions that there can be no assurance it will successfully negotiate a termination or otherwise resolve these obligations outside of a bankruptcy process, highlighting significant uncertainty around remaining liabilities.
Lyra Therapeutics, Inc. reports that Nasdaq has moved to delist its common stock after determining under Listing Rule 5101 that the company is a “public shell” without an operating business. Nasdaq cited Lyra’s prior decision to suspend development of its lead product candidate LYR-210 and a reduction in force that terminated nearly all employees, including shifting the CEO and CFO to consultant roles.
Nasdaq also asserted Lyra has not met the minimum $2,500,000 stockholders’ equity requirement in Listing Rule 5550(b), despite an earlier compliance extension and Lyra’s request for more time to complete a financing. Lyra has requested a hearing before a Nasdaq Hearings Panel, which temporarily stays any suspension and Form 25-NSE filing, but there is no assurance its appeal will succeed.
Lyra Therapeutics disclosed a major restructuring centered on suspending further development of LYR-210, its lead drug candidate for chronic rhinosinusitis, and implementing a cost reduction plan that includes a workforce reduction affecting substantially all remaining employees, effective January 12, 2026. The company expects to incur charges related to severance, benefits and associated costs, and plans to amend this report once it can estimate those amounts.
In connection with the plan, the employment of CEO, President and Chair Dr. Maria Palasis and CFO and Treasurer Jason Cavalier was terminated on January 9, 2026, with each moving to a consulting role supporting the pursuit of strategic alternatives and continuing as principal executive and principal financial officer, respectively. Their consulting agreements provide monthly fees of $78,125 for Dr. Palasis and $55,555.50 for Mr. Cavalier, change-of-control vesting for time-based restricted stock units, and potential transaction bonuses if the change-in-control purchase price exceeds $5,000,000.
The board has decided to cease product development operations while continuing to evaluate strategic alternatives, assisted by SSG Capital Advisors, LLC. As of September 30, 2025, Lyra held approximately $22.1 million in cash, cash equivalents and short-term investments and currently expects its cash runway to extend to the third quarter of 2026.
Lyra Therapeutics, Inc. filed a report noting that on September 4, 2025 it posted a new corporate presentation on its website. Company representatives may use this presentation in discussions with investors, analysts, and other interested parties.
The presentation is provided as Exhibit 99.1 to the report and is incorporated by reference, giving stakeholders a centralized source for updated company information. Lyra’s common stock trades on the Nasdaq Capital Market under the symbol LYRA.
Lyra Therapeutics reported receipt of a Nasdaq deficiency letter because its stockholders' equity was approximately $1.6 million as of June 30, 2025, below the Nasdaq Capital Market minimum requirement of $2.5 million. The filing states the deficiency letter has no immediate effect on the listing or trading of the company's common stock, which will continue to trade on Nasdaq under the symbol LYRA. The company points investors to its Annual Report and Quarterly Report for risk disclosures and reiterates standard forward-looking statements caution. The report is dated August 22, 2025, and signed by CFO Jason Cavalier.
Lyra Therapeutics filed an 8-K reporting it announced financial results for the quarter ended June 30, 2025. The filing states the company furnished a press release as Exhibit 99.1 and posted a corporate presentation on its website, furnished as Exhibit 99.2. Both exhibits are expressly described as "furnished, and not filed," and the company disclaims any obligation to update the presentation. The filing identifies Lyra's common stock as trading under the symbol LYRA on The Nasdaq Capital Market and indicates the company is an emerging growth company. The report is signed by CFO Jason Cavalier on August 12, 2025.
Lyra Therapeutics (NASDAQ:LYRA) filed an 8-K on June 26, 2025 disclosing a registered direct offering and concurrent private placement.
The company sold 273,012 common shares, 150,360 pre-funded warrants (exercise $0.001) and 846,744 private warrants (exercise $11.56) at a combined price of $11.81, generating about $4.3 million in net proceeds.
- H.C. Wainwright earns a 7 % placement fee plus 6.5 % on any future warrant cash exercise.
- Private warrants are immediately exercisable, expire 24 months after the resale registration statement is declared effective and include Black-Scholes cash-out rights upon a fundamental transaction.
- Beneficial-ownership caps: 9.99 % for pre-funded warrants, 4.99 % (optionally 9.99 %) for private warrants.
- Proceeds will fund working capital and further clinical, manufacturing and pre-commercial activities for LYR-210.
No additional material events were reported.
Lyra Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirement (Listing Rule 5550(a)(2)). The company received written confirmation from Nasdaq on June 13, 2025 that its common stock maintained a bid price above $1.00 for 12 consecutive business days from May 28, 2025 to June 12, 2025.
Key details:
- Trading Symbol: LYRA on Nasdaq Capital Market
- Stock Type: Common Stock ($0.001 par value per share)
- Company Status: Emerging growth company
- Compliance Issue: Now resolved and closed
This development removes a significant regulatory concern for the company and ensures continued listing on the Nasdaq Capital Market. The filing was signed by CFO Jason Cavalier on June 23, 2025.